These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27842256)

  • 1. Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation.
    Hellyer S; Leach K; Gregory KJ
    Curr Opin Pharmacol; 2017 Feb; 32():49-55. PubMed ID: 27842256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4.
    Volpi C; Fallarino F; Mondanelli G; Macchiarulo A; Grohmann U
    Expert Opin Drug Discov; 2018 May; 13(5):411-423. PubMed ID: 29486616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.
    Gregory KJ; Noetzel MJ; Niswender CM
    Prog Mol Biol Transl Sci; 2013; 115():61-121. PubMed ID: 23415092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurobiological Insights from mGlu Receptor Allosteric Modulation.
    O'Brien DE; Conn PJ
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26647381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation.
    Gregory KJ; Conn PJ
    Mol Pharmacol; 2015 Jul; 88(1):188-202. PubMed ID: 25808929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
    Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
    Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors.
    Stansley BJ; Conn PJ
    Trends Pharmacol Sci; 2019 Apr; 40(4):240-252. PubMed ID: 30824180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 - present).
    Qunies AM; Emmitte KA
    Expert Opin Ther Pat; 2021 Aug; 31(8):687-708. PubMed ID: 33719801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.
    Foster DJ; Conn PJ
    Neuron; 2017 May; 94(3):431-446. PubMed ID: 28472649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric modulation of metabotropic glutamate receptors.
    Sheffler DJ; Gregory KJ; Rook JM; Conn PJ
    Adv Pharmacol; 2011; 62():37-77. PubMed ID: 21907906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.
    Yin S; Niswender CM
    Cell Signal; 2014 Oct; 26(10):2284-97. PubMed ID: 24793301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate receptors as drug targets: what's new?
    Nicoletti F; Bruno V; Ngomba RT; Gradini R; Battaglia G
    Curr Opin Pharmacol; 2015 Feb; 20():89-94. PubMed ID: 25506748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
    Célanire S; Campo B
    Expert Opin Drug Discov; 2012 Mar; 7(3):261-80. PubMed ID: 22468956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modulation of metabotropic glutamate receptors in alcohol use disorder: Insights from preclinical investigations.
    Johnson KA; Lovinger DM
    Adv Pharmacol; 2020; 88():193-232. PubMed ID: 32416868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
    Lesage A; Steckler T
    Eur J Pharmacol; 2010 Aug; 639(1-3):2-16. PubMed ID: 20371230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease.
    Luessen DJ; Conn PJ
    Pharmacol Rev; 2022 Jul; 74(3):630-661. PubMed ID: 35710132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic frontiers for metabotropic glutamate receptors.
    Niswender CM; Jones CK; Conn PJ
    Curr Top Med Chem; 2005; 5(9):847-57. PubMed ID: 16178730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders.
    Spooren WP; Gasparini F; Salt TE; Kuhn R
    Trends Pharmacol Sci; 2001 Jul; 22(7):331-7. PubMed ID: 11431019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators.
    Bennett KA; Christopher JA; Tehan BG
    Adv Pharmacol; 2020; 88():35-58. PubMed ID: 32416871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel class of succinimide-derived negative allosteric modulators of metabotropic glutamate receptor subtype 1 provides insight into a disconnect in activity between the rat and human receptors.
    Cho HP; Engers DW; Venable DF; Niswender CM; Lindsley CW; Conn PJ; Emmitte KA; Rodriguez AL
    ACS Chem Neurosci; 2014 Jul; 5(7):597-610. PubMed ID: 24798819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.